Logo image of CLNN

CLENE INC (CLNN) Stock Fundamental Analysis

USA - NASDAQ:CLNN - US1856342019 - Common Stock

8.25 USD
-0.35 (-4.01%)
Last: 10/13/2025, 8:00:00 PM
8.26 USD
+0.01 (+0.12%)
After Hours: 10/13/2025, 8:00:00 PM
Fundamental Rating

2

CLNN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative. CLNN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLNN had negative earnings in the past year.
In the past year CLNN has reported a negative cash flow from operations.
In the past 5 years CLNN always reported negative net income.
In the past 5 years CLNN always reported negative operating cash flow.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CLNN has a Return On Assets of -134.26%. This is amonst the worse of the industry: CLNN underperforms 83.58% of its industry peers.
Industry RankSector Rank
ROA -134.26%
ROE N/A
ROIC N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

CLNN has a better Gross Margin (80.42%) than 85.07% of its industry peers.
CLNN's Gross Margin has improved in the last couple of years.
CLNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLNN has more shares outstanding
Compared to 5 years ago, CLNN has more shares outstanding
Compared to 1 year ago, CLNN has a worse debt to assets ratio.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CLNN has an Altman-Z score of -20.36. This is a bad value and indicates that CLNN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.36, CLNN is doing worse than 85.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.36
ROIC/WACCN/A
WACC10.31%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.58 indicates that CLNN should not have too much problems paying its short term obligations.
The Current ratio of CLNN (1.58) is worse than 80.60% of its industry peers.
A Quick Ratio of 1.56 indicates that CLNN should not have too much problems paying its short term obligations.
CLNN's Quick ratio of 1.56 is on the low side compared to the rest of the industry. CLNN is outperformed by 80.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.56
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.43% over the past year.
CLNN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.59%.
CLNN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -21.98% yearly.
EPS 1Y (TTM)11.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.42%
Revenue 1Y (TTM)-35.59%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-70.33%

3.2 Future

CLNN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.57% yearly.
The Revenue is expected to grow by 308.25% on average over the next years. This is a very strong growth
EPS Next Y66.09%
EPS Next 2Y29.59%
EPS Next 3Y29.79%
EPS Next 5Y24.57%
Revenue Next Year-36.6%
Revenue Next 2Y204.64%
Revenue Next 3Y557.45%
Revenue Next 5Y308.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLNN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CLNN's earnings are expected to grow with 29.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.59%
EPS Next 3Y29.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLENE INC

NASDAQ:CLNN (10/13/2025, 8:00:00 PM)

After market: 8.26 +0.01 (+0.12%)

8.25

-0.35 (-4.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners12.26%
Inst Owner Change0%
Ins Owners20.36%
Ins Owner Change-0.08%
Market Cap83.08M
Analysts81.54
Price Target32.3 (291.52%)
Short Float %4.96%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.58%
Min EPS beat(2)-61.56%
Max EPS beat(2)90.71%
EPS beat(4)2
Avg EPS beat(4)-13.28%
Min EPS beat(4)-91.95%
Max EPS beat(4)90.71%
EPS beat(8)5
Avg EPS beat(8)7.99%
EPS beat(12)7
Avg EPS beat(12)3.83%
EPS beat(16)10
Avg EPS beat(16)34.41%
Revenue beat(2)1
Avg Revenue beat(2)-4.98%
Min Revenue beat(2)-49.89%
Max Revenue beat(2)39.93%
Revenue beat(4)1
Avg Revenue beat(4)-11.64%
Min Revenue beat(4)-49.89%
Max Revenue beat(4)39.93%
Revenue beat(8)2
Avg Revenue beat(8)-11.84%
Revenue beat(12)5
Avg Revenue beat(12)18.38%
Revenue beat(16)7
Avg Revenue beat(16)14.51%
PT rev (1m)3.1%
PT rev (3m)-11.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.72%
EPS NY rev (1m)1.74%
EPS NY rev (3m)-17.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 290.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.95
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.03
BVpS-0.85
TBVpS-0.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -134.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.42%
FCFM N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.13%
Cap/Sales 0.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.56
Altman-Z -20.36
F-Score3
WACC10.31%
ROIC/WACCN/A
Cap/Depr(3y)176.04%
Cap/Depr(5y)141.46%
Cap/Sales(3y)385.66%
Cap/Sales(5y)305.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.42%
EPS Next Y66.09%
EPS Next 2Y29.59%
EPS Next 3Y29.79%
EPS Next 5Y24.57%
Revenue 1Y (TTM)-35.59%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-70.33%
Revenue Next Year-36.6%
Revenue Next 2Y204.64%
Revenue Next 3Y557.45%
Revenue Next 5Y308.25%
EBIT growth 1Y26.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.66%
EBIT Next 3Y25.74%
EBIT Next 5Y44.82%
FCF growth 1Y51.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.61%
OCF growth 3YN/A
OCF growth 5YN/A